Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TOP2A | P11388 | 9/20 | 0.56 |
| ▸ | TOP2B | Q02880 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CLK2 | P49760 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TOP1 | P11387 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clinafloxacin SCHEMBL8596801 | 1.00 | ALDH1A1 (1.00) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL33959 | 1.00 | ALDH1A1 (1.00) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL33960 | 1.00 | ALDH1A1 (1.00) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL29682535 | 0.99 | ALDH1A1 (0.98) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL5571098 | 0.99 | ALDH1A1 (0.98) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL193234 | 0.99 | ALDH1A1 (0.98) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL193233 | 0.99 | ALDH1A1 (0.98) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL29288561 | 0.99 | ALDH1A1 (0.98) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL14973954 | 0.98 | ALDH1A1 (0.96) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL8566142 | 0.96 | ALDH1A1 (0.93) | ALDH1A1POLBOPRM1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4434588-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2026-04-08 | — | — | EP | claimed |
| EP-3711797-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2025-02-12 | — | — | EP | claimed |
| EP-4434588-A2 | AEROSOL DELIVERY DEVICE AND METHOD OF OPERATING THE AEROSOL DELIVERY DEVICE | PARI Pharma GmbH (DE) | 2024-09-25 | — | — | EP | claimed |
| EP-3122757-B1 | CHARGED LINKERS AND THEIR USES FOR CONJUGATION | HANGZHOU DAC BIOTECH CO LTD (CN) | 2023-09-06 | — | — | EP | claimed |
| WO-2022166129-A1 | SCREENING METHOD FOR HETEROLOGOUS COMPETITIVE ANTIGEN FOR USE IN IMPROVEMENT OF IMMUNODETECTION SENSITIVITY | 江西煌上煌集团食品股份有限公司 | 2022-08-11 | — | — | WO | claimed |
| EP-3265083-B1 | SUBSTITUTED UREA DEPSIPEPTIDE ANALOGS AS ACTIVATORS OF THE CLPP ENDOPEPTIDASE | ST JUDE CHILDRENS RES HOSPITAL (US) | 2022-07-06 | — | — | EP | claimed |
| EP-4434588-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4713056-A1 | DEVICE FOR PROVIDING CONTINUED BREATH GUIDANCE, METHOD OF OPERATING AN INHALATION DEVICE, INHALATION DEVICE AND INHALATION DEVICE SYSTEM FOR PROVIDING INHALATION PROCESS/BREATH GUIDING | Pari Medical Holding GmbH (DE) | 2026-03-25 | — | — | EP | disclosed |
| EP-4712837-A1 | METHOD OF OPERATING AN INHALATION DEVICE, INHALATION DEVICE, INHALATION DEVICE SYSTEM FOR PROVIDING INHALATION PROCESS FEEDBACK AND DEVICE FOR PROVIDING FEEDBACK GUIDANCE | Pari Medical Holding GmbH (DE) | 2026-03-25 | — | — | EP | disclosed |
| US-12558353-B2 | Method of reducing pulmonary exacerbations in respiratory disease patients | CELLTAXIS, LLC (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4659255-A1 | MEDICAL EVALUATION METHOD, AEROSOL NEBULIZER AND MEDICAL EVALUATION SYSTEM | Pari Medical Holding GmbH (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-20250347055-A1 | WATER RESISTANT MATERIALS FOR FOOD-SAFE USES | JL DARLING LLC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12404635-B2 | Water resistant materials for food-safe uses | JL DARLING LLC (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2022166129-A1 | SCREENING METHOD FOR HETEROLOGOUS COMPETITIVE ANTIGEN FOR USE IN IMPROVEMENT OF IMMUNODETECTION SENSITIVITY | 江西煌上煌集团食品股份有限公司 | 2022-08-11 | — | — | WO | disclosed |
| WO-2022155495-A1 | METHODS FOR OPTIMIZING CFTR-MODULATOR THERAPY | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-07-21 | — | — | WO | disclosed |
| US-20220218834-A1 | APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-14 | — | — | US | disclosed |
| EP-4003200-A1 | ANTIBACTERIAL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS USING SAME | The Rockefeller University (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2022081867-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | NORTH CAROLINA STATE UNIVERSITY (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3972646-A1 | APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF | Ohio State Innovation Foundation (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022016216-A1 | BIOCOMPATIBLE POLYMER COMPOSITIONS | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558353-B2 | Method of reducing pulmonary exacerbations in respiratory disease patients | SERPINB1, CFTR, LTA4H | ALDH1A1 881/4885POLB 2742/4885OPRM1 4301/4885 |
| US-20220218834-A1 | APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF | HBG1, HBG2, LPO | ALDH1A1 3209/4885POLB 1274/4885OPRM1 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.